Servier CDMO offers a variety of tableting and encapsulation options to optimize your product’s therapeutic performance. Our tablet capabilities range from immediate, controlled and modified release to film and sugar coating, and we have the equipment and expertise to encapsulate powders, granules and micro-tablets.
Servier CDMO has high-performance production capabilities for a full range of dosage forms and product groups, including liquids, sprays and powders. Our manufacturing and packaging suites have separate air handling and filtration systems to ensure full quality control and assurance across the lifecycle of your product.
Servier CDMO provides custom manufacturing of APIs and HPAPIs from worldwide facilities. Our industry-leading methodologies, combined with state-of-the-art containment tools, enables us to handle your project from development through commercial phases, addressing any technical and regulatory challenges that may arise.
We manufacture pharmaceutical intermediates from state-of-the-art cGMP and FDA-approved chemical facilities around the world. Leveraging our integrated network of R&D, production and supply chain expertise, we provide intermediate manufacturing for both GMP and non-GMP requirements, from kilogram scale to several metric tons.
At Servier CDMO, we provide a number of cost-effective primary and secondary packaging options, including blisters, sachets and bottles. We strictly adhere to global standards for serialization and aggregation, and provide tamper-evident packaging and labeling in line with EU requirements.
Our state-of-the-art manufacturing facility in Gidy has dedicated production units for liquid, spray and dry forms manufacturing, as well as an additional biotechnology unit launching in 2019. Gidy provides formulation and analytical development, scale-up manufacturing and packaging for distribution to 148 countries.
Servier’s Oril Industrie facility in Bolbec specializes in the development and manufacture of intermediates, APIs and HPAPIs for worldwide distribution.
To improve productivity and efficiency, reduce costs and environmental impacts and enhance quality assurance, Servier CDMO is implementing an operational excellence (OPEX) continuous improvement program. Mini-transformations across multiple sites are enabling the company to provide significant added value to its clients and build greater trust with all stakeholders.
Servier Group is proud to announce that it will develop its presence in the US market through the oncology therapeutic area. Servier CDMO, in accordance with the group’s strategy, continues to develop its services for High Potent drugs in API and drug product.